Restricted accessResearch articleFirst published online 2007-09
Long-Term Results of a Phase-I/II Study of Sequential High-Dose Chemotherapy with Autologous Stem Cell Transplantation in the Initial Treatment of Aggressive Non-Hodgkin's Lymphoma
To improve the survival of patients with aggressive non-Hodgkin's lymphoma, we evaluated a risk-adapted therapeutic approach using high-dose (HD) or conventional-dose (CD) chemotherapy (CT) for poor-risk and good-risk patients, respectively.
Methods
Twenty patients were treated in each group. In both groups, the first chemotherapy cycle consisted of dexamethasone, vincristine, ifosfamide, and etoposide. Thereafter, the CD or HD patients received 3 or 2 cycles of dexamethasone, vincristine, epirubicin, and cyclophosphamide, respectively, followed by 1 cycle of dexamethasone, carboplatin, and etoposide. In the HD group cyclophosphamide, epirubicin, carboplatin, and etoposide were dose-escalated by a factor of 6, 3, 3, and 3, respectively, as compared to the CD group, and autologous peripheral blood stem cells were administered after each HD-CT cycle.
Results
Grade III-IV toxicities were neutropenia and thrombocytopenia (100%), anemia (55%), and stomatitis (30%) in patients with HD-CT, and neutropenia (90%) in patients with CD-CT. One toxic death occurred in a patient with HD-CT. The overall response rate was 100% in HD-CT patients, including 70% complete remissions, and 80% in CD-CT patients, including 60% complete remissions. The 10-year overall survival was 55% for patients with HD-CT and 80% for patients with CD-CT.
Conclusions
The risk-adapted treatment approach showed tolerable toxicities and was associated with encouraging results.
ShippM.A., HarringtonD.P., AndersonJ.R., ArmitageJ.O., BonadonnaG., BrittingerG., CabanillasF., CanellosG.P., CoiffierB., ConnorsJ.M., CowanR.A., CrowtherD., DahlbergS., EngelhardM., FisherR.I., GisselbrechtC., HorningS.J., LepageE., ListerT.A., MeerwaldtJ.H., MontserratE., NissenN.I., OkenM.M., PetersonB.A., TondiniC., VelasquezW.S., YeapB.Y.: A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project.N Engl J Med, 329: 987–994, 1993.
3.
PfreundschuhM., TrumperL., KloessM., SchmitsR., FellerA.C., RubeC., RudolphC., ReiserM., HossfeldD.K., EimermacherH., HasencleverD., SchmitzN., LoefflerM.: Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.Blood, 104: 634–641, 2004.
4.
CoiffierB., LepageE., BriereJ., HerbrechtR., TillyH., BouabdallahR., MorelP., Van Den NesteE., SallesG., GaulardP., ReyesF., LederlinP., GisselbrechtC.: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.N Engl J Med, 346: 235–242, 2002.
5.
FeugierP., Van HoofA., SebbanC., Solal-CelignyP., BouabdallahR., FermeC., ChristianB., LepageE., TillyH., MorschhauserF., GaulardP., SallesG., BoslyA., GisselbrechtC., ReyesF., CoiffierB.: Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.J Clin Oncol, 23: 4117–4126, 2005.
6.
PhilipT., GuglielmiC., HagenbeekA., SomersR., Van der LelieH., BronD., SonneveldP., GisselbrechtC., CahnJ.Y., HarousseauJ.L.: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.N Engl J Med, 333: 1540–1545, 1995.
7.
ShippM.A., AbeloffM.D., AntmanK.H., CarrollG., HagenbeekA., LoefflerM., MontserratE., RadfordJ.A., SallesG., SchmitzN., SymannM., ArmitageJ.O., PhilipT., CoiffierB.: International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury.J Clin Oncol, 17: 423–429, 1999.
BonadonnaG., GianniL., SantoroA., BonfanteV., BidoliP., CasaliP., DemicheliR., ValagussaP.: Drugs ten years later: epirubicin.Ann Oncol, 4: 359–369, 1993.
10.
TortiF.M., BristowM.M., LumB.L., CarterS.K., HowesA.E., AstonD.A., BrownB.W., HanniganJ.F., MeyersF.J., MitchellE.P., BillinghamM.E.: Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy.Cancer Res, 46: 3722–3727, 1986.
11.
OlivieriA., SantiniG., PattiC., ChisesiT., De SouzaC., RubagottiA., AversaS., BillioA., PorcelliniA., CandelaM., CenturioniR., CongiuA.M., BrunoriM., NatiS., SprianoM., VimercatiR., MarinoG., ContuA., TedeschiL., MajolinoI., CrugnolaM., SertoliM.R.: Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin's lymphoma: long-term results by the NHLCSG.Ann Oncol, 16: 1941–1948, 2005.
12.
KaiserU., UebelackerI., AbelU., BirkmannJ., TrumperL., SchmalenbergH., KarakasT., MetznerB., HossfeldD.K., BischoffH.G., FrankeA., ReiserM., MullerP., MantovaniL., GrundeisM., RothmannF., von SeydewitzC.U., MestersR.M., SteinhauerE.U., KrahlD., SchumacherK., KnebaM., BaudisM., SchmitzN., PfabR., KopplerH., ParwareschR., PfreundschuhM., HavemannK.: Randomized study to evaluate the use of high-dose therapy as part of primary treatment for “aggressive” lymphoma.J Clin Oncol, 20: 4413–4419, 2002.
13.
HarrisN.L., JaffeE.S., SteinH., BanksP.M., ChanJ.K., ClearyM.L., DelsolG., De Wolf-PeetersC., FaliniB., GatterK.C., GroganT.M., IsaacsonP.G., KnowlesD.M., MasonD.Y., Muller-HermelinkH.K., PileriS.A., PirisM.A., RalfkiaerE., WarnkeR.A.: A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.Blood, 84: 1361–1392, 1994.
14.
KaplanE.L., MeierP.: Nonparametric estimation from incomplete observations.J Am Stat Assoc, 53: 457–481, 1958.
15.
SchüttP., PassonJ., EbelingP., WeltA., MüllerS., MetzK., MoritzT., SeeberS., NowrousianM.: Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.Eur J Haematol, 78: 93–182, 2007.
16.
FisherR.I., GaynorE.R., DahlbergS., OkenM.M., GroganT.M., MizeE.M., GlickJ.H., ColtmanC.A., MillerT.P.: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.N Engl J Med, 328: 1002–1006, 1993.
17.
VitoloU., LiberatiA.M., CabrasM.G., FedericoM., AngelucciE., BaldiniL., BoccominiC., BrugiatelliM., CalviR., CicconeG., GenuaA., DeliliersG.L., LevisA., ParvisG., PavoneE., SalviF., SborgiaM., GalloE.: High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an “Intergruppo Italiano Linfomi” randomized trial.Haematologica, 90: 793–801, 2005.
18.
GlassB., KloessM., BentzM., SchlimokG., BerdelW.E., FellerA., TrumperL., LoefflerM., PfreundschuhM., SchmitzN.: Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma.Blood, 107: 3058–3064, 2006.
19.
HaiounC., LepageE., GisselbrechtC., SallesG., CoiffierB., BriceP., BoslyA., MorelP., NouvelC., TillyH., LederlinP., SebbanC., BriereJ., GaulardP., ReyesF.: Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol–a Groupe d'Etude des Lymphomes de l'Adulte study.J Clin Oncol, 18: 3025–3030, 2000.
MartelliM., GherlinzoniF., De RenzoA., ZinzaniP.L., De VivoA., CantonettiM., FaliniB., StortiS., MeloniG., RizzoM., MolinariA.L., LauriaF., MorettiL., LautaV.M., MazzaP., GuardigniL., PescarmonaE., PileriS.A., MandelliF., TuraS.: Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial.J Clin Oncol, 21: 1255–1262, 2003.
22.
FumoleauP., RocheH., KerbratP., BonneterreJ., RomestaingP., FargeotP., NamerM., MonnierA., MontcuquetP., GoudierM.J., LuporsiE.: Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results.Ann Oncol, 17: 85–92, 2006.
23.
PragaC., BerettaG., VigoP.L., LenazG.R., PolliniC., BonadonnaG., CanettaR., CastellaniR., VillaE., GallagherC.G., von MelchnerH., HayatM., RibaudP., De WaschG., MattssonW., HeinzR., WaldnerR., KolaricK., BuehnerR., Ten Bokkel-HuyninckW., PerevodchikovaN.I., ManziukL.A., SennH.J., MayrA.C.: Adriamycin cardiotoxicity: a survey of 1273 patients.Cancer Treat Rep, 63: 827–834, 1979.
24.
BasserR.L., AbrahamR., ToL.B., FoxR.M., GreenM.D.: Cardiac effects of high-dose epirubicin and cyclophosphamide in women with poor prognosis breast cancer.Ann Oncol, 10: 53–58, 1999.
25.
GianniA.M., BregniM., SienaS., BrambillaC., Di NicolaM., LombardiF., GandolaL., TarellaC., PileriA., RavagnaniF., ValagussaP., BonadonnaG.: High-dose chemotherapy and autologous bone marrow transplantation compared with MA-COP-B in aggressive B-cell lymphoma.N Engl J Med, 336: 1290–1297, 1997.
26.
StewartD.A., BahlisN., ValentineK., BaloghA., SavoieL., MorrisD.G., JonesA., BrownC., RussellJ.A.: Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma.Blood, 107: 4623–4627, 2006.
27.
PettengellR., RadfordJ.A., MorgensternG.R., ScarffeJ.H., HarrisM., WollP.J., DeakinD.P., RyderD., WilkinsonP.M., CrowtherD.: Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin's lymphoma.J Clin Oncol, 14: 586–592, 1996.
28.
Kluin-NelemansH.C., ZagonelV., AnastasopoulouA., BronD., RoozendaalK.J., NoordijkE.M., MussonH., TeodorovicI., MaesB., CarboneA., CardeP., ThomasJ.: Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study.J Natl Cancer Inst, 93: 22–30, 2001.
29.
MilpiedN., DeconinckE., GaillardF., DelwailV., FoussardC., BerthouC., GressinR., LucasV., ColombatP., HarousseauJ.L.: Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support.N Engl J Med, 350: 1287–1295, 2004.
30.
BertzH., ZeiserR., LangeW., FetscherS., WallerC.F., FinkeJ.: Long-term follow-up after high-dose chemotherapy and autologous stem-cell transplantation for high-grade B-cell lymphoma suggests an improved outcome for high-risk patients with respect to the age-adjusted International Prognostic Index.Ann Oncol, 15: 1419–1424, 2004.
31.
NademaneeA., MolinaA., O'DonnellM.R., DagisA., SnyderD.S., ParkerP., SteinA., SmithE., PlanasI., KashyapA., SpielbergerR., FungH., WongK.K., SomloG., MargolinK., ChowW., SniecinskiI., VoraN., BlumeK.G., NilandJ., FormanS.J.: Results of high-dose therapy and autologous bone marrow/stem cell transplantation during remission in poor-risk intermediate- and high-grade lymphoma: international index high and high-intermediate risk group.Blood, 90: 3844–3852, 1997.
32.
SchmitzN., KloessM., ReiserM., BerdelW.E., MetznerB., DorkenB., KnebaM., TrumperL., LoefflerM., PfreundschuhM., GlassB.: Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma.Cancer, 106: 136–145, 2006.
33.
HiddemannW., KnebaM., DreylingM., SchmitzN., LengfelderE., SchmitsR., ReiserM., MetznerB., HarderH., HegewischBeckerS., FischerT., KropffM., ReisH.E., FreundM., WormannB., FuchsR., PlankerM., SchimkeJ., EimermacherH., TrumperL., AldaoudA., ParwareschR., UnterhaltM.: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.Blood, 106: 3725–3732, 2005.
34.
ForstpointnerR., DreylingM., ReppR., HermannS., HanelA., MetznerB., PottC., HartmannF., RothmannF., RohrbergR., BockH.P., WandtH., UnterhaltM., HiddemannW.: The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.Blood, 104: 3064–3071, 2004.
35.
KhouriI.F., SalibaR.M., HosingC., OkorojiG.J., AcholonuS., AnderliniP., CourielD., De LimaM., DonatoM.L., FayadL., GiraltS., JonesR., KorblingM., MaadaniF., ManningJ.T., ProB., ShpallE., YounesA., McLaughlinP., ChamplinR.E.: Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas.J Clin Oncol, 23: 2240–2247, 2005.
36.
HequetO., LeQ.H., MoulletI., PauliE., SallesG., EspinouseD., DumontetC., ThieblemontC., ArnaudP., AntalD., BouafiaF., CoiffierB.: Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults.J Clin Oncol, 22: 1864–1871, 2004.
37.
ArmitageJ.O., FyfeM.A., LewisJ.: Long-term remission durability and functional status of patients treated for diffuse histiocytic lymphoma with the CHOP regimen.J Clin Oncol, 2: 898–902, 1984.
